Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of dasatinib (BMS-354825) in subjects with chronic myelogenous leukemia with accelerated or myeloid or lymphoid blast phase or Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant to or intolerant of imatinib mesylate

Next Previous
Trial Profile

Study of dasatinib (BMS-354825) in subjects with chronic myelogenous leukemia with accelerated or myeloid or lymphoid blast phase or Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant to or intolerant of imatinib mesylate

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 10 Dec 2007 Status changed from in progress to completed.
  • 08 Aug 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top